Emma Guttman-Yassky, MD, PhD

Emma Guttman-Yassky, MD, PhD, discusses findings from an abrocitinib on-off JADE REGIMEN analysis and what they may mean for disease modification in atopic dermatitis.

The study represents a repurposing strategy, using dupilumab as a tool compound to probe whether immune-targeted therapy can address a biologically defined subgroup of MDD.

The combination of rapid onset and durable response positions zumilokibart as a potentially attractive first-line biologic option.

Join leading experts at the 2025 Inflammatory Skin Disease Summit to explore groundbreaking research and innovations in dermatologic care and therapies.

A late-breaking EADV presentation revealed that ritlecitinib significantly improved outcomes in patients with multiple forms of scarring alopecia.

The biologic’s less frequent injections could ease logistical and emotional strain for patients with atopic dermatitis and their families.

By targeting IL-13, APG777 may allow for less frequent dosing compared to existing biologics.

At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.

Discover promising advancements in vitiligo treatments, including innovative therapies and combination approaches that enhance skin repigmentation and improve patient quality of life.

Many patients with severe AD are unaware of newer, more effective treatments.